Investigational drug · Phase 2
AK129
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "AK129"
First trial start
2025
Jan 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK129", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer Stage IIIB/IV
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Colorectal Adenocarcinoma
- Advanced Solid Tumors
- Classic Hodgkin Lymphoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Head and neck cancer · Hodgkin lymphoma · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AK129" as an intervention, largest first.
AkesoIndustry
NCT06642792 · 280 participants (planned) · Start Jan 17, 2025 · Primary completion Nov 2027
Drug: AK129; AK117 · For: Classic Hodgkin Lymphoma
Sites: Beijing, China
- AK129 Combination Therapy for Advanced Solid TumorsPivotal-lookingRecruiting
AkesoIndustry
NCT06943820 · 230 participants (planned) · Start May 21, 2025 · Primary completion Dec 2026
Drug: AK129(dose 1); Pemetrexed and 12 more · For: Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal Adenocarcinoma and 1 more
Sites: Shenyang, China
AkesoIndustry
NCT05645276 · 57 participants · Start Mar 3, 2023 · Primary completion Jun 9, 2026
Drug: AK129 IV infusion · For: Advanced Malignant Tumors(Stage IA-IB)
Sites: Beijing, China
AkesoIndustry
NCT06586294 · 35 participants · Start Sep 30, 2024 · Primary completion Apr 20, 2026
Drug: Drug: AK129 Drug:oxaliplatin Drug:capecitabine; Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine · For: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Sites: Hanzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.